View Financial HealthSunmax Biotechnology 배당 및 자사주 매입배당 기준 점검 1/6Sunmax Biotechnology 은(는) 현재 수익률이 3.11% 인 배당금 지급 회사입니다.핵심 정보3.1%배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률29.7%다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향91%최근 배당 및 자사주 매입 업데이트Upcoming Dividend • Mar 24Upcoming dividend of NT$12.10 per shareEligible shareholders must have bought the stock before 31 March 2026. Payment date: 05 May 2026. Payout ratio and cash payout ratio are on the higher end at 88% and 83% respectively. Trailing yield: 3.0%. Lower than top quartile of Taiwanese dividend payers (5.3%). Higher than average of industry peers (0.9%).Upcoming Dividend • Jul 28Upcoming dividend of NT$11.60 per shareEligible shareholders must have bought the stock before 04 August 2025. Payment date: 28 August 2025. Payout ratio and cash payout ratio are on the higher end at 87% and 98% respectively. Trailing yield: 2.8%. Lower than top quartile of Taiwanese dividend payers (5.3%). Higher than average of industry peers (1.1%).Upcoming Dividend • Jul 10Upcoming dividend of NT$11.00 per shareEligible shareholders must have bought the stock before 17 July 2024. Payment date: 08 August 2024. Payout ratio and cash payout ratio are on the higher end at 89% and 76% respectively. Trailing yield: 3.4%. Lower than top quartile of Taiwanese dividend payers (4.2%). Higher than average of industry peers (2.5%).Upcoming Dividend • Jul 11Upcoming dividend of NT$9.50 per share at 4.1% yieldEligible shareholders must have bought the stock before 18 July 2023. Payment date: 08 August 2023. Payout ratio is a comfortable 47% and this is well supported by cash flows. Trailing yield: 4.1%. Lower than top quartile of Taiwanese dividend payers (5.4%). Higher than average of industry peers (2.6%).Upcoming Dividend • Jul 06Upcoming dividend of NT$4.40 per shareEligible shareholders must have bought the stock before 13 July 2022. Payment date: 29 July 2022. Payout ratio is on the higher end at 76%, and the cash payout ratio is above 100%. Trailing yield: 3.7%. Lower than top quartile of Taiwanese dividend payers (6.6%). Higher than average of industry peers (2.9%).Upcoming Dividend • Sep 15Upcoming dividend of NT$2.00 per shareEligible shareholders must have bought the stock before 22 September 2021. Payment date: 15 October 2021. Trailing yield: 2.4%. Lower than top quartile of Taiwanese dividend payers (5.2%). In line with average of industry peers (2.3%).모든 업데이트 보기Recent updatesReported Earnings • May 16First quarter 2026 earnings released: EPS: NT$4.00 (vs NT$4.10 in 1Q 2025)First quarter 2026 results: EPS: NT$4.00 (down from NT$4.10 in 1Q 2025). Revenue: NT$564.8m (up 1.9% from 1Q 2025). Net income: NT$221.6m (flat on 1Q 2025). Profit margin: 39% (down from 40% in 1Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has increased by 17% per year, which means it is tracking significantly ahead of earnings growth.Buy Or Sell Opportunity • May 15Now 21% overvaluedOver the last 90 days, the stock has fallen 1.3% to NT$385. The fair value is estimated to be NT$318, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 11%.Upcoming Dividend • Mar 24Upcoming dividend of NT$12.10 per shareEligible shareholders must have bought the stock before 31 March 2026. Payment date: 05 May 2026. Payout ratio and cash payout ratio are on the higher end at 88% and 83% respectively. Trailing yield: 3.0%. Lower than top quartile of Taiwanese dividend payers (5.3%). Higher than average of industry peers (0.9%).Reported Earnings • Mar 14Full year 2025 earnings released: EPS: NT$13.33 (vs NT$12.48 in FY 2024)Full year 2025 results: EPS: NT$13.33 (up from NT$12.48 in FY 2024). Revenue: NT$2.03b (up 11% from FY 2024). Net income: NT$725.7m (up 6.8% from FY 2024). Profit margin: 36% (down from 37% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has increased by 43% per year, which means it is tracking significantly ahead of earnings growth.공고 • Mar 13Sunmax Biotechnology Co., Ltd., Annual General Meeting, Jun 15, 2026Sunmax Biotechnology Co., Ltd., Annual General Meeting, Jun 15, 2026. Location: no,8, chih fu rd., jhongshan district, taipei city TaiwanBuy Or Sell Opportunity • Jan 28Now 20% overvaluedThe stock has been flat over the last 90 days, currently trading at NT$393. The fair value is estimated to be NT$326, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 13%.Buy Or Sell Opportunity • Jan 12Now 20% overvaluedThe stock has been flat over the last 90 days, currently trading at NT$394. The fair value is estimated to be NT$327, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 13%.Buy Or Sell Opportunity • Dec 22Now 20% overvaluedOver the last 90 days, the stock has fallen 3.6% to NT$396. The fair value is estimated to be NT$329, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 13%.Buy Or Sell Opportunity • Dec 01Now 20% overvaluedOver the last 90 days, the stock has fallen 3.3% to NT$393. The fair value is estimated to be NT$327, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 13%.Reported Earnings • Nov 15Third quarter 2025 earnings released: EPS: NT$3.48 (vs NT$3.15 in 3Q 2024)Third quarter 2025 results: EPS: NT$3.48 (up from NT$3.15 in 3Q 2024). Revenue: NT$503.6m (up 10% from 3Q 2024). Net income: NT$189.7m (up 11% from 3Q 2024). Profit margin: 38% (in line with 3Q 2024). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 42% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Aug 15Second quarter 2025 earnings released: EPS: NT$2.84 (vs NT$3.35 in 2Q 2024)Second quarter 2025 results: EPS: NT$2.84 (down from NT$3.35 in 2Q 2024). Revenue: NT$460.1m (up 1.4% from 2Q 2024). Net income: NT$154.9m (down 15% from 2Q 2024). Profit margin: 34% (down from 40% in 2Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has increased by 38% per year, which means it is tracking significantly ahead of earnings growth.Upcoming Dividend • Jul 28Upcoming dividend of NT$11.60 per shareEligible shareholders must have bought the stock before 04 August 2025. Payment date: 28 August 2025. Payout ratio and cash payout ratio are on the higher end at 87% and 98% respectively. Trailing yield: 2.8%. Lower than top quartile of Taiwanese dividend payers (5.3%). Higher than average of industry peers (1.1%).Reported Earnings • May 15First quarter 2025 earnings released: EPS: NT$4.10 (vs NT$3.24 in 1Q 2024)First quarter 2025 results: EPS: NT$4.10 (up from NT$3.24 in 1Q 2024). Revenue: NT$554.2m (up 30% from 1Q 2024). Net income: NT$223.3m (up 27% from 1Q 2024). Profit margin: 40% (in line with 1Q 2024). Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has increased by 65% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Apr 16Investor sentiment improves as stock rises 22%After last week's 22% share price gain to NT$417, the stock trades at a trailing P/E ratio of 33.4x. Average trailing P/E is 30x in the Biotechs industry in Taiwan. Total returns to shareholders of 270% over the past three years.New Risk • Mar 30New major risk - Dividend sustainabilityThe dividend is not well covered by earnings and cash flows. Payout ratio: 93% Cash payout ratio: 121% Dividend yield: 3.0% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Payout ratio: 93% Cash payout ratio: 121% High level of non-cash earnings (28% accrual ratio).Reported Earnings • Mar 20Full year 2024 earnings released: EPS: NT$12.47 (vs NT$11.49 in FY 2023)Full year 2024 results: EPS: NT$12.47 (up from NT$11.49 in FY 2023). Revenue: NT$1.82b (up 7.6% from FY 2023). Net income: NT$679.4m (up 8.6% from FY 2023). Profit margin: 37% (in line with FY 2023). Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has increased by 46% per year, which means it is tracking significantly ahead of earnings growth.공고 • Mar 17Sunmax Biotechnology Co., Ltd., Annual General Meeting, Jun 18, 2025Sunmax Biotechnology Co., Ltd., Annual General Meeting, Jun 18, 2025. Location: no,8, chih fu rd., jhongshan district, taipei city TaiwanReported Earnings • Nov 17Third quarter 2024 earnings released: EPS: NT$3.15 (vs NT$3.39 in 3Q 2023)Third quarter 2024 results: EPS: NT$3.15 (down from NT$3.39 in 3Q 2023). Revenue: NT$457.5m (down 3.5% from 3Q 2023). Net income: NT$171.6m (down 7.0% from 3Q 2023). Profit margin: 38% (down from 39% in 3Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has increased by 50% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Aug 17Second quarter 2024 earnings released: EPS: NT$3.35 (vs NT$2.65 in 2Q 2023)Second quarter 2024 results: EPS: NT$3.35 (up from NT$2.65 in 2Q 2023). Revenue: NT$453.7m (up 8.7% from 2Q 2023). Net income: NT$182.4m (up 26% from 2Q 2023). Profit margin: 40% (up from 35% in 2Q 2023). Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has increased by 54% per year, which means it is tracking significantly ahead of earnings growth.Upcoming Dividend • Jul 10Upcoming dividend of NT$11.00 per shareEligible shareholders must have bought the stock before 17 July 2024. Payment date: 08 August 2024. Payout ratio and cash payout ratio are on the higher end at 89% and 76% respectively. Trailing yield: 3.4%. Lower than top quartile of Taiwanese dividend payers (4.2%). Higher than average of industry peers (2.5%).Buy Or Sell Opportunity • Jun 17Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 54% to NT$324. The fair value is estimated to be NT$268, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 22% over the last 3 years. Earnings per share has grown by 37%.New Risk • Jun 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (6.5% average weekly change).Buy Or Sell Opportunity • May 30Now 23% overvalued after recent price riseOver the last 90 days, the stock has risen 60% to NT$327. The fair value is estimated to be NT$265, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 22% over the last 3 years. Earnings per share has grown by 37%.Valuation Update With 7 Day Price Move • May 27Investor sentiment improves as stock rises 19%After last week's 19% share price gain to NT$288, the stock trades at a trailing P/E ratio of 23.3x. Average trailing P/E is 42x in the Biotechs industry in Taiwan. Total returns to shareholders of 344% over the past three years.Reported Earnings • May 18First quarter 2024 earnings released: EPS: NT$3.24 (vs NT$2.35 in 1Q 2023)First quarter 2024 results: EPS: NT$3.24 (up from NT$2.35 in 1Q 2023). Revenue: NT$427.6m (up 8.8% from 1Q 2023). Net income: NT$176.4m (up 38% from 1Q 2023). Profit margin: 41% (up from 33% in 1Q 2023). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has increased by 50% per year, which means it is tracking significantly ahead of earnings growth.공고 • Apr 12Sunmax Biotechnology Co., Ltd., Annual General Meeting, Jun 28, 2024Sunmax Biotechnology Co., Ltd., Annual General Meeting, Jun 28, 2024.Reported Earnings • Mar 19Full year 2023 earnings released: EPS: NT$11.49 (vs NT$9.80 in FY 2022)Full year 2023 results: EPS: NT$11.49 (up from NT$9.80 in FY 2022). Revenue: NT$1.69b (up 21% from FY 2022). Net income: NT$625.7m (up 17% from FY 2022). Profit margin: 37% (down from 38% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 37% per year and the company’s share price has also increased by 37% per year.New Risk • Nov 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 5.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by earnings (97% payout ratio). Share price has been volatile over the past 3 months (5.4% average weekly change).Reported Earnings • Nov 15Third quarter 2023 earnings released: EPS: NT$3.39 (vs NT$2.52 in 3Q 2022)Third quarter 2023 results: EPS: NT$3.39 (up from NT$2.52 in 3Q 2022). Revenue: NT$473.9m (up 30% from 3Q 2022). Net income: NT$184.4m (up 34% from 3Q 2022). Profit margin: 39% (up from 38% in 3Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 42% per year whereas the company’s share price has increased by 41% per year.Reported Earnings • Aug 14Second quarter 2023 earnings released: EPS: NT$2.65 (vs NT$2.55 in 2Q 2022)Second quarter 2023 results: EPS: NT$2.65 (up from NT$2.55 in 2Q 2022). Revenue: NT$417.4m (up 30% from 2Q 2022). Net income: NT$144.5m (up 4.0% from 2Q 2022). Profit margin: 35% (down from 43% in 2Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has only increased by 38% per year, which means it is significantly lagging earnings growth.Upcoming Dividend • Jul 11Upcoming dividend of NT$9.50 per share at 4.1% yieldEligible shareholders must have bought the stock before 18 July 2023. Payment date: 08 August 2023. Payout ratio is a comfortable 47% and this is well supported by cash flows. Trailing yield: 4.1%. Lower than top quartile of Taiwanese dividend payers (5.4%). Higher than average of industry peers (2.6%).Valuation Update With 7 Day Price Move • May 12Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to NT$242, the stock trades at a trailing P/E ratio of 24.6x. Average trailing P/E is 46x in the Biotechs industry in Taiwan. Total returns to shareholders of 245% over the past three years.Valuation Update With 7 Day Price Move • Apr 14Investor sentiment improves as stock rises 23%After last week's 23% share price gain to NT$176, the stock trades at a trailing P/E ratio of 18x. Average trailing P/E is 43x in the Biotechs industry in Taiwan. Total returns to shareholders of 194% over the past three years.Valuation Update With 7 Day Price Move • Dec 15Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to NT$140, the stock trades at a trailing P/E ratio of 15x. Average trailing P/E is 37x in the Biotechs industry in Taiwan. Total returns to shareholders of 85% over the past three years.Reported Earnings • Nov 19Third quarter 2022 earnings released: EPS: NT$2.52 (vs NT$0.76 in 3Q 2021)Third quarter 2022 results: EPS: NT$2.52 (up from NT$0.76 in 3Q 2021). Revenue: NT$363.6m (up 44% from 3Q 2021). Net income: NT$137.3m (up 230% from 3Q 2021). Profit margin: 38% (up from 17% in 3Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth.Reported Earnings • Aug 18Second quarter 2022 earnings released: EPS: NT$2.55 (vs NT$0.82 in 2Q 2021)Second quarter 2022 results: EPS: NT$2.55 (up from NT$0.82 in 2Q 2021). Revenue: NT$321.9m (up 37% from 2Q 2021). Net income: NT$139.0m (up 212% from 2Q 2021). Profit margin: 43% (up from 19% in 2Q 2021). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 23% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Aug 01Investor sentiment improved over the past weekAfter last week's 15% share price gain to NT$154, the stock trades at a trailing P/E ratio of 26.6x. Average trailing P/E is 32x in the Biotechs industry in Taiwan. Total returns to shareholders of 115% over the past three years.Upcoming Dividend • Jul 06Upcoming dividend of NT$4.40 per shareEligible shareholders must have bought the stock before 13 July 2022. Payment date: 29 July 2022. Payout ratio is on the higher end at 76%, and the cash payout ratio is above 100%. Trailing yield: 3.7%. Lower than top quartile of Taiwanese dividend payers (6.6%). Higher than average of industry peers (2.9%).공고 • Apr 07Sunmax Biotechnology Co., Ltd., Annual General Meeting, Jun 20, 2022Sunmax Biotechnology Co., Ltd., Annual General Meeting, Jun 20, 2022.Reported Earnings • Apr 03Full year 2021 earnings released: EPS: NT$4.51 (vs NT$4.37 in FY 2020)Full year 2021 results: EPS: NT$4.51 (up from NT$4.37 in FY 2020). Revenue: NT$1.04b (up 21% from FY 2020). Net income: NT$245.6m (up 3.2% from FY 2020). Profit margin: 24% (down from 28% in FY 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has only increased by 28% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Mar 11Investor sentiment improved over the past weekAfter last week's 16% share price gain to NT$121, the stock trades at a trailing P/E ratio of 26.3x. Average trailing P/E is 25x in the Biotechs industry in Taiwan. Total returns to shareholders of 101% over the past three years.Valuation Update With 7 Day Price Move • Feb 09Investor sentiment improved over the past weekAfter last week's 22% share price gain to NT$118, the stock trades at a trailing P/E ratio of 25.6x. Average trailing P/E is 26x in the Biotechs industry in Taiwan. Total returns to shareholders of 171% over the past three years.Reported Earnings • Nov 17Third quarter 2021 earnings released: EPS NT$0.76 (vs NT$0.35 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: NT$252.4m (up 31% from 3Q 2020). Net income: NT$41.6m (up 120% from 3Q 2020). Profit margin: 17% (up from 9.8% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has only increased by 29% per year, which means it is significantly lagging earnings growth.Upcoming Dividend • Sep 15Upcoming dividend of NT$2.00 per shareEligible shareholders must have bought the stock before 22 September 2021. Payment date: 15 October 2021. Trailing yield: 2.4%. Lower than top quartile of Taiwanese dividend payers (5.2%). In line with average of industry peers (2.3%).Reported Earnings • Aug 18Second quarter 2021 earnings released: EPS NT$0.81 (vs NT$1.12 in 2Q 2020)The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: NT$234.7m (up 20% from 2Q 2020). Net income: NT$44.5m (down 27% from 2Q 2020). Profit margin: 19% (down from 31% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has only increased by 37% per year, which means it is significantly lagging earnings growth.Reported Earnings • May 16First quarter 2021 earnings released: EPS NT$1.16 (vs NT$1.03 in 1Q 2020)The company reported a solid first quarter result with improved earnings and revenues, although profit margins were weaker. First quarter 2021 results: Revenue: NT$267.0m (up 56% from 1Q 2020). Net income: NT$62.9m (up 12% from 1Q 2020). Profit margin: 24% (down from 33% in 1Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has only increased by 25% per year, which means it is significantly lagging earnings growth.Reported Earnings • Apr 01Full year 2020 earnings released: EPS NT$4.37 (vs NT$1.84 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: NT$855.9m (up 44% from FY 2019). Net income: NT$238.1m (up 137% from FY 2019). Profit margin: 28% (up from 17% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has only increased by 28% per year, which means it is significantly lagging earnings growth.분석 기사 • Feb 28Investors Who Bought Sunmax Biotechnology (GTSM:4728) Shares Three Years Ago Are Now Up 166%It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes...분석 기사 • Feb 02Is Sunmax Biotechnology Co., Ltd. (GTSM:4728) The Right Choice For A Smart Dividend Investor?Today we'll take a closer look at Sunmax Biotechnology Co., Ltd. ( GTSM:4728 ) from a dividend investor's perspective...Is New 90 Day High Low • Dec 30New 90-day high: NT$78.90The company is up 14% from its price of NT$69.40 on 30 September 2020. The Taiwanese market is up 15% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is flat over the same period.분석 기사 • Dec 20Sunmax Biotechnology Co., Ltd.'s (GTSM:4728) Stock Is Going Strong: Is the Market Following Fundamentals?Most readers would already be aware that Sunmax Biotechnology's (GTSM:4728) stock increased significantly by 12% over...Is New 90 Day High Low • Dec 08New 90-day high: NT$72.70The company is up 14% from its price of NT$64.00 on 09 September 2020. The Taiwanese market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 5.0% over the same period.분석 기사 • Nov 24Is Sunmax Biotechnology's (GTSM:4728) Share Price Gain Of 152% Well Earned?The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But in contrast you can...Reported Earnings • Nov 15Third quarter 2020 earnings released: EPS NT$0.35The company reported a soft third quarter result with weaker earnings and profit margins, although revenues were improved. Third quarter 2020 results: Revenue: NT$193.0m (up 1.8% from 3Q 2019). Net income: NT$18.9m (down 68% from 3Q 2019). Profit margin: 9.8% (down from 31% in 3Q 2019). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has only increased by 37% per year, which means it is significantly lagging earnings growth.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 배당금 지급이 안정적인 반면, 4728 은(는) 배당금을 지급한 지 10년도 채 되지 않았습니다.배당금 증가: 4728 의 배당금 지급이 증가했지만 회사는 8 년 동안만 배당금을 지급했습니다.배당 수익률 vs 시장Sunmax Biotechnology 배당 수익률 vs 시장4728의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (4728)3.1%시장 하위 25% (TW)1.5%시장 상위 25% (TW)5.0%업계 평균 (Biotechs)0.4%분석가 예측 (4728) (최대 3년)n/a주목할만한 배당금: 4728 의 배당금( 3.11% )은 TW 시장에서 배당금 지급자의 하위 25%( 1.51% )보다 높습니다.고배당: 4728 의 배당금( 3.11% )은 TW 시장에서 배당금 지급자의 상위 25%( 5.04% )와 비교해 낮습니다.주주 대상 이익 배당수익 보장: 지급 비율 ( 91% )이 높기 때문에 4728 의 배당금 지급은 수익으로 잘 충당되지 않습니다.주주 현금 배당현금 흐름 범위: 현금 지급 비율 ( 90.8% )이 높기 때문에 4728 의 배당금 지급은 현금 흐름으로 잘 충당되지 않습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YTW 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/08/13 18:14종가2026/08/13 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Sunmax Biotechnology Co., Ltd.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Upcoming Dividend • Mar 24Upcoming dividend of NT$12.10 per shareEligible shareholders must have bought the stock before 31 March 2026. Payment date: 05 May 2026. Payout ratio and cash payout ratio are on the higher end at 88% and 83% respectively. Trailing yield: 3.0%. Lower than top quartile of Taiwanese dividend payers (5.3%). Higher than average of industry peers (0.9%).
Upcoming Dividend • Jul 28Upcoming dividend of NT$11.60 per shareEligible shareholders must have bought the stock before 04 August 2025. Payment date: 28 August 2025. Payout ratio and cash payout ratio are on the higher end at 87% and 98% respectively. Trailing yield: 2.8%. Lower than top quartile of Taiwanese dividend payers (5.3%). Higher than average of industry peers (1.1%).
Upcoming Dividend • Jul 10Upcoming dividend of NT$11.00 per shareEligible shareholders must have bought the stock before 17 July 2024. Payment date: 08 August 2024. Payout ratio and cash payout ratio are on the higher end at 89% and 76% respectively. Trailing yield: 3.4%. Lower than top quartile of Taiwanese dividend payers (4.2%). Higher than average of industry peers (2.5%).
Upcoming Dividend • Jul 11Upcoming dividend of NT$9.50 per share at 4.1% yieldEligible shareholders must have bought the stock before 18 July 2023. Payment date: 08 August 2023. Payout ratio is a comfortable 47% and this is well supported by cash flows. Trailing yield: 4.1%. Lower than top quartile of Taiwanese dividend payers (5.4%). Higher than average of industry peers (2.6%).
Upcoming Dividend • Jul 06Upcoming dividend of NT$4.40 per shareEligible shareholders must have bought the stock before 13 July 2022. Payment date: 29 July 2022. Payout ratio is on the higher end at 76%, and the cash payout ratio is above 100%. Trailing yield: 3.7%. Lower than top quartile of Taiwanese dividend payers (6.6%). Higher than average of industry peers (2.9%).
Upcoming Dividend • Sep 15Upcoming dividend of NT$2.00 per shareEligible shareholders must have bought the stock before 22 September 2021. Payment date: 15 October 2021. Trailing yield: 2.4%. Lower than top quartile of Taiwanese dividend payers (5.2%). In line with average of industry peers (2.3%).
Reported Earnings • May 16First quarter 2026 earnings released: EPS: NT$4.00 (vs NT$4.10 in 1Q 2025)First quarter 2026 results: EPS: NT$4.00 (down from NT$4.10 in 1Q 2025). Revenue: NT$564.8m (up 1.9% from 1Q 2025). Net income: NT$221.6m (flat on 1Q 2025). Profit margin: 39% (down from 40% in 1Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has increased by 17% per year, which means it is tracking significantly ahead of earnings growth.
Buy Or Sell Opportunity • May 15Now 21% overvaluedOver the last 90 days, the stock has fallen 1.3% to NT$385. The fair value is estimated to be NT$318, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 11%.
Upcoming Dividend • Mar 24Upcoming dividend of NT$12.10 per shareEligible shareholders must have bought the stock before 31 March 2026. Payment date: 05 May 2026. Payout ratio and cash payout ratio are on the higher end at 88% and 83% respectively. Trailing yield: 3.0%. Lower than top quartile of Taiwanese dividend payers (5.3%). Higher than average of industry peers (0.9%).
Reported Earnings • Mar 14Full year 2025 earnings released: EPS: NT$13.33 (vs NT$12.48 in FY 2024)Full year 2025 results: EPS: NT$13.33 (up from NT$12.48 in FY 2024). Revenue: NT$2.03b (up 11% from FY 2024). Net income: NT$725.7m (up 6.8% from FY 2024). Profit margin: 36% (down from 37% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has increased by 43% per year, which means it is tracking significantly ahead of earnings growth.
공고 • Mar 13Sunmax Biotechnology Co., Ltd., Annual General Meeting, Jun 15, 2026Sunmax Biotechnology Co., Ltd., Annual General Meeting, Jun 15, 2026. Location: no,8, chih fu rd., jhongshan district, taipei city Taiwan
Buy Or Sell Opportunity • Jan 28Now 20% overvaluedThe stock has been flat over the last 90 days, currently trading at NT$393. The fair value is estimated to be NT$326, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 13%.
Buy Or Sell Opportunity • Jan 12Now 20% overvaluedThe stock has been flat over the last 90 days, currently trading at NT$394. The fair value is estimated to be NT$327, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 13%.
Buy Or Sell Opportunity • Dec 22Now 20% overvaluedOver the last 90 days, the stock has fallen 3.6% to NT$396. The fair value is estimated to be NT$329, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 13%.
Buy Or Sell Opportunity • Dec 01Now 20% overvaluedOver the last 90 days, the stock has fallen 3.3% to NT$393. The fair value is estimated to be NT$327, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 13%.
Reported Earnings • Nov 15Third quarter 2025 earnings released: EPS: NT$3.48 (vs NT$3.15 in 3Q 2024)Third quarter 2025 results: EPS: NT$3.48 (up from NT$3.15 in 3Q 2024). Revenue: NT$503.6m (up 10% from 3Q 2024). Net income: NT$189.7m (up 11% from 3Q 2024). Profit margin: 38% (in line with 3Q 2024). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 42% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Aug 15Second quarter 2025 earnings released: EPS: NT$2.84 (vs NT$3.35 in 2Q 2024)Second quarter 2025 results: EPS: NT$2.84 (down from NT$3.35 in 2Q 2024). Revenue: NT$460.1m (up 1.4% from 2Q 2024). Net income: NT$154.9m (down 15% from 2Q 2024). Profit margin: 34% (down from 40% in 2Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has increased by 38% per year, which means it is tracking significantly ahead of earnings growth.
Upcoming Dividend • Jul 28Upcoming dividend of NT$11.60 per shareEligible shareholders must have bought the stock before 04 August 2025. Payment date: 28 August 2025. Payout ratio and cash payout ratio are on the higher end at 87% and 98% respectively. Trailing yield: 2.8%. Lower than top quartile of Taiwanese dividend payers (5.3%). Higher than average of industry peers (1.1%).
Reported Earnings • May 15First quarter 2025 earnings released: EPS: NT$4.10 (vs NT$3.24 in 1Q 2024)First quarter 2025 results: EPS: NT$4.10 (up from NT$3.24 in 1Q 2024). Revenue: NT$554.2m (up 30% from 1Q 2024). Net income: NT$223.3m (up 27% from 1Q 2024). Profit margin: 40% (in line with 1Q 2024). Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has increased by 65% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Apr 16Investor sentiment improves as stock rises 22%After last week's 22% share price gain to NT$417, the stock trades at a trailing P/E ratio of 33.4x. Average trailing P/E is 30x in the Biotechs industry in Taiwan. Total returns to shareholders of 270% over the past three years.
New Risk • Mar 30New major risk - Dividend sustainabilityThe dividend is not well covered by earnings and cash flows. Payout ratio: 93% Cash payout ratio: 121% Dividend yield: 3.0% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Payout ratio: 93% Cash payout ratio: 121% High level of non-cash earnings (28% accrual ratio).
Reported Earnings • Mar 20Full year 2024 earnings released: EPS: NT$12.47 (vs NT$11.49 in FY 2023)Full year 2024 results: EPS: NT$12.47 (up from NT$11.49 in FY 2023). Revenue: NT$1.82b (up 7.6% from FY 2023). Net income: NT$679.4m (up 8.6% from FY 2023). Profit margin: 37% (in line with FY 2023). Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has increased by 46% per year, which means it is tracking significantly ahead of earnings growth.
공고 • Mar 17Sunmax Biotechnology Co., Ltd., Annual General Meeting, Jun 18, 2025Sunmax Biotechnology Co., Ltd., Annual General Meeting, Jun 18, 2025. Location: no,8, chih fu rd., jhongshan district, taipei city Taiwan
Reported Earnings • Nov 17Third quarter 2024 earnings released: EPS: NT$3.15 (vs NT$3.39 in 3Q 2023)Third quarter 2024 results: EPS: NT$3.15 (down from NT$3.39 in 3Q 2023). Revenue: NT$457.5m (down 3.5% from 3Q 2023). Net income: NT$171.6m (down 7.0% from 3Q 2023). Profit margin: 38% (down from 39% in 3Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has increased by 50% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Aug 17Second quarter 2024 earnings released: EPS: NT$3.35 (vs NT$2.65 in 2Q 2023)Second quarter 2024 results: EPS: NT$3.35 (up from NT$2.65 in 2Q 2023). Revenue: NT$453.7m (up 8.7% from 2Q 2023). Net income: NT$182.4m (up 26% from 2Q 2023). Profit margin: 40% (up from 35% in 2Q 2023). Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has increased by 54% per year, which means it is tracking significantly ahead of earnings growth.
Upcoming Dividend • Jul 10Upcoming dividend of NT$11.00 per shareEligible shareholders must have bought the stock before 17 July 2024. Payment date: 08 August 2024. Payout ratio and cash payout ratio are on the higher end at 89% and 76% respectively. Trailing yield: 3.4%. Lower than top quartile of Taiwanese dividend payers (4.2%). Higher than average of industry peers (2.5%).
Buy Or Sell Opportunity • Jun 17Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 54% to NT$324. The fair value is estimated to be NT$268, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 22% over the last 3 years. Earnings per share has grown by 37%.
New Risk • Jun 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (6.5% average weekly change).
Buy Or Sell Opportunity • May 30Now 23% overvalued after recent price riseOver the last 90 days, the stock has risen 60% to NT$327. The fair value is estimated to be NT$265, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 22% over the last 3 years. Earnings per share has grown by 37%.
Valuation Update With 7 Day Price Move • May 27Investor sentiment improves as stock rises 19%After last week's 19% share price gain to NT$288, the stock trades at a trailing P/E ratio of 23.3x. Average trailing P/E is 42x in the Biotechs industry in Taiwan. Total returns to shareholders of 344% over the past three years.
Reported Earnings • May 18First quarter 2024 earnings released: EPS: NT$3.24 (vs NT$2.35 in 1Q 2023)First quarter 2024 results: EPS: NT$3.24 (up from NT$2.35 in 1Q 2023). Revenue: NT$427.6m (up 8.8% from 1Q 2023). Net income: NT$176.4m (up 38% from 1Q 2023). Profit margin: 41% (up from 33% in 1Q 2023). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has increased by 50% per year, which means it is tracking significantly ahead of earnings growth.
공고 • Apr 12Sunmax Biotechnology Co., Ltd., Annual General Meeting, Jun 28, 2024Sunmax Biotechnology Co., Ltd., Annual General Meeting, Jun 28, 2024.
Reported Earnings • Mar 19Full year 2023 earnings released: EPS: NT$11.49 (vs NT$9.80 in FY 2022)Full year 2023 results: EPS: NT$11.49 (up from NT$9.80 in FY 2022). Revenue: NT$1.69b (up 21% from FY 2022). Net income: NT$625.7m (up 17% from FY 2022). Profit margin: 37% (down from 38% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 37% per year and the company’s share price has also increased by 37% per year.
New Risk • Nov 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 5.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by earnings (97% payout ratio). Share price has been volatile over the past 3 months (5.4% average weekly change).
Reported Earnings • Nov 15Third quarter 2023 earnings released: EPS: NT$3.39 (vs NT$2.52 in 3Q 2022)Third quarter 2023 results: EPS: NT$3.39 (up from NT$2.52 in 3Q 2022). Revenue: NT$473.9m (up 30% from 3Q 2022). Net income: NT$184.4m (up 34% from 3Q 2022). Profit margin: 39% (up from 38% in 3Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 42% per year whereas the company’s share price has increased by 41% per year.
Reported Earnings • Aug 14Second quarter 2023 earnings released: EPS: NT$2.65 (vs NT$2.55 in 2Q 2022)Second quarter 2023 results: EPS: NT$2.65 (up from NT$2.55 in 2Q 2022). Revenue: NT$417.4m (up 30% from 2Q 2022). Net income: NT$144.5m (up 4.0% from 2Q 2022). Profit margin: 35% (down from 43% in 2Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has only increased by 38% per year, which means it is significantly lagging earnings growth.
Upcoming Dividend • Jul 11Upcoming dividend of NT$9.50 per share at 4.1% yieldEligible shareholders must have bought the stock before 18 July 2023. Payment date: 08 August 2023. Payout ratio is a comfortable 47% and this is well supported by cash flows. Trailing yield: 4.1%. Lower than top quartile of Taiwanese dividend payers (5.4%). Higher than average of industry peers (2.6%).
Valuation Update With 7 Day Price Move • May 12Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to NT$242, the stock trades at a trailing P/E ratio of 24.6x. Average trailing P/E is 46x in the Biotechs industry in Taiwan. Total returns to shareholders of 245% over the past three years.
Valuation Update With 7 Day Price Move • Apr 14Investor sentiment improves as stock rises 23%After last week's 23% share price gain to NT$176, the stock trades at a trailing P/E ratio of 18x. Average trailing P/E is 43x in the Biotechs industry in Taiwan. Total returns to shareholders of 194% over the past three years.
Valuation Update With 7 Day Price Move • Dec 15Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to NT$140, the stock trades at a trailing P/E ratio of 15x. Average trailing P/E is 37x in the Biotechs industry in Taiwan. Total returns to shareholders of 85% over the past three years.
Reported Earnings • Nov 19Third quarter 2022 earnings released: EPS: NT$2.52 (vs NT$0.76 in 3Q 2021)Third quarter 2022 results: EPS: NT$2.52 (up from NT$0.76 in 3Q 2021). Revenue: NT$363.6m (up 44% from 3Q 2021). Net income: NT$137.3m (up 230% from 3Q 2021). Profit margin: 38% (up from 17% in 3Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Aug 18Second quarter 2022 earnings released: EPS: NT$2.55 (vs NT$0.82 in 2Q 2021)Second quarter 2022 results: EPS: NT$2.55 (up from NT$0.82 in 2Q 2021). Revenue: NT$321.9m (up 37% from 2Q 2021). Net income: NT$139.0m (up 212% from 2Q 2021). Profit margin: 43% (up from 19% in 2Q 2021). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 23% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Aug 01Investor sentiment improved over the past weekAfter last week's 15% share price gain to NT$154, the stock trades at a trailing P/E ratio of 26.6x. Average trailing P/E is 32x in the Biotechs industry in Taiwan. Total returns to shareholders of 115% over the past three years.
Upcoming Dividend • Jul 06Upcoming dividend of NT$4.40 per shareEligible shareholders must have bought the stock before 13 July 2022. Payment date: 29 July 2022. Payout ratio is on the higher end at 76%, and the cash payout ratio is above 100%. Trailing yield: 3.7%. Lower than top quartile of Taiwanese dividend payers (6.6%). Higher than average of industry peers (2.9%).
공고 • Apr 07Sunmax Biotechnology Co., Ltd., Annual General Meeting, Jun 20, 2022Sunmax Biotechnology Co., Ltd., Annual General Meeting, Jun 20, 2022.
Reported Earnings • Apr 03Full year 2021 earnings released: EPS: NT$4.51 (vs NT$4.37 in FY 2020)Full year 2021 results: EPS: NT$4.51 (up from NT$4.37 in FY 2020). Revenue: NT$1.04b (up 21% from FY 2020). Net income: NT$245.6m (up 3.2% from FY 2020). Profit margin: 24% (down from 28% in FY 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has only increased by 28% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Mar 11Investor sentiment improved over the past weekAfter last week's 16% share price gain to NT$121, the stock trades at a trailing P/E ratio of 26.3x. Average trailing P/E is 25x in the Biotechs industry in Taiwan. Total returns to shareholders of 101% over the past three years.
Valuation Update With 7 Day Price Move • Feb 09Investor sentiment improved over the past weekAfter last week's 22% share price gain to NT$118, the stock trades at a trailing P/E ratio of 25.6x. Average trailing P/E is 26x in the Biotechs industry in Taiwan. Total returns to shareholders of 171% over the past three years.
Reported Earnings • Nov 17Third quarter 2021 earnings released: EPS NT$0.76 (vs NT$0.35 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: NT$252.4m (up 31% from 3Q 2020). Net income: NT$41.6m (up 120% from 3Q 2020). Profit margin: 17% (up from 9.8% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has only increased by 29% per year, which means it is significantly lagging earnings growth.
Upcoming Dividend • Sep 15Upcoming dividend of NT$2.00 per shareEligible shareholders must have bought the stock before 22 September 2021. Payment date: 15 October 2021. Trailing yield: 2.4%. Lower than top quartile of Taiwanese dividend payers (5.2%). In line with average of industry peers (2.3%).
Reported Earnings • Aug 18Second quarter 2021 earnings released: EPS NT$0.81 (vs NT$1.12 in 2Q 2020)The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: NT$234.7m (up 20% from 2Q 2020). Net income: NT$44.5m (down 27% from 2Q 2020). Profit margin: 19% (down from 31% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has only increased by 37% per year, which means it is significantly lagging earnings growth.
Reported Earnings • May 16First quarter 2021 earnings released: EPS NT$1.16 (vs NT$1.03 in 1Q 2020)The company reported a solid first quarter result with improved earnings and revenues, although profit margins were weaker. First quarter 2021 results: Revenue: NT$267.0m (up 56% from 1Q 2020). Net income: NT$62.9m (up 12% from 1Q 2020). Profit margin: 24% (down from 33% in 1Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has only increased by 25% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Apr 01Full year 2020 earnings released: EPS NT$4.37 (vs NT$1.84 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: NT$855.9m (up 44% from FY 2019). Net income: NT$238.1m (up 137% from FY 2019). Profit margin: 28% (up from 17% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has only increased by 28% per year, which means it is significantly lagging earnings growth.
분석 기사 • Feb 28Investors Who Bought Sunmax Biotechnology (GTSM:4728) Shares Three Years Ago Are Now Up 166%It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes...
분석 기사 • Feb 02Is Sunmax Biotechnology Co., Ltd. (GTSM:4728) The Right Choice For A Smart Dividend Investor?Today we'll take a closer look at Sunmax Biotechnology Co., Ltd. ( GTSM:4728 ) from a dividend investor's perspective...
Is New 90 Day High Low • Dec 30New 90-day high: NT$78.90The company is up 14% from its price of NT$69.40 on 30 September 2020. The Taiwanese market is up 15% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is flat over the same period.
분석 기사 • Dec 20Sunmax Biotechnology Co., Ltd.'s (GTSM:4728) Stock Is Going Strong: Is the Market Following Fundamentals?Most readers would already be aware that Sunmax Biotechnology's (GTSM:4728) stock increased significantly by 12% over...
Is New 90 Day High Low • Dec 08New 90-day high: NT$72.70The company is up 14% from its price of NT$64.00 on 09 September 2020. The Taiwanese market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 5.0% over the same period.
분석 기사 • Nov 24Is Sunmax Biotechnology's (GTSM:4728) Share Price Gain Of 152% Well Earned?The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But in contrast you can...
Reported Earnings • Nov 15Third quarter 2020 earnings released: EPS NT$0.35The company reported a soft third quarter result with weaker earnings and profit margins, although revenues were improved. Third quarter 2020 results: Revenue: NT$193.0m (up 1.8% from 3Q 2019). Net income: NT$18.9m (down 68% from 3Q 2019). Profit margin: 9.8% (down from 31% in 3Q 2019). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has only increased by 37% per year, which means it is significantly lagging earnings growth.